Publications by authors named "Amy Racine"

Claim this Profile
D
Developing a prototype for federated analysis to enhance privacy and enable trustworthy access to COVID-19 research data.
Solmaz Eradat Oskoui, Matthew Retford, Eoghan Forde, Rodrigo Barnes, Karen J Hunter, Amy Racine

Int J Med Inform· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
Angelika Caputo, Amy Racine, Ines Paule, Pierre N Tariot, Jessica B Langbaum

Alzheimers Res Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach.
Yuan Xiong, Etienne Pigeolet, Zufar Mulyukov, Philippe Margaron, Amy Racine

Contemp Clin Trials· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect.
Zufar Mulyukov, Sebastian Weber, Etienne Pigeolet, Andreas Clemens, Thorsten Lehr, Amy Racine

CPT Pharmacometrics Syst Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A flexible Bayesian approach for modeling monotonic dose-response relationships in drug development trials.
David Ohlssen, Amy Racine

J Biopharm Stat· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing a non-inferiority study in kidney transplantation: a case study.
Steffen Witte, Heinz Schmidli, Anthony O'Hagan, Amy Racine

Pharm Stat· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian models for subgroup analysis in clinical trials.
Hayley E Jones, David I Ohlssen, Beat Neuenschwander, Amy Racine, Michael Branson

Clin Trials· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
George D Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
Frank Bretz, Heinz Schmidli, Franz König, Amy Racine, Willi Maurer

Biom J· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
Heinz Schmidli, Frank Bretz, Amy Racine, Willi Maurer

Biom J· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
Ian Judson, Peiming Ma, Bin Peng, Jaap Verweij, Amy Racine

Cancer Chemother Pharmacol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?
Ferdinand Rombout, Leon Aarons, Mats Karlsson, Anthony Man, France Mentré, Amy Racine

J Pharmacokinet Pharmacodyn· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis